Search Results - "Gregory, Walter M."

Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment by Tulotta, Claudia, Lefley, Diane V, Freeman, Katy, Gregory, Walter M, Hanby, Andrew M, Heath, Paul R, Nutter, Faith, Wilkinson, J Mark, Spicer-Hadlington, Amy R, Liu, Xinming, Bradbury, Steven M J, Hambley, Lisa, Cookson, Victoria, Allocca, Gloria, Kruithof de Julio, Marianna, Coleman, Robert E, Brown, Janet E, Holen, Ingunn, Ottewell, Penelope D

“…Breast cancer bone metastases are incurable, highlighting the need for new therapeutic targets. After colonizing bone, breast cancer cells remain dormant,…”
Get full text

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study by RAWSTRON, Andy C, CHILD, J. Anthony, ROSS, Fiona M, COOK, Gordon, JACKSON, Graham H, MORGAN, Gareth J, OWEN, Roger G, DE TUTE, Ruth M, DAVIES, Faith E, GREGORY, Walter M, BELL, Sue E, SZUBERT, Alexander J, NAVARRO-COY, Nuria, DRAYSON, Mark T, FEYLER, Sylvia

“…To investigate the prognostic value of minimal residual disease (MRD) assessment in patients with multiple myeloma treated in the MRC (Medical Research…”
Get full text

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction by Rawstron, Andy C., Gregory, Walter M., de Tute, Ruth M., Davies, Faith E., Bell, Sue E., Drayson, Mark T., Cook, Gordon, Jackson, Graham H., Morgan, Gareth J., Child, J. Anthony, Owen, Roger G.

“…The detection of minimal residual disease (MRD) in myeloma using a 0.01% threshold (10−4) after treatment is an independent predictor of progression-free…”
Get full text

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial by Morgan, Gareth J, Dr, Prof, Davies, Faith E, MD, Gregory, Walter M, Prof, Cocks, Kim, MSc, Bell, Sue E, DPhil, Szubert, Alex J, MSc, Navarro-Coy, Nuria, MPhil, Drayson, Mark T, MD, Owen, Roger G, MD, Feyler, Sylvia, MD, Ashcroft, A John, MD, Ross, Fiona, DPhil, Byrne, Jennifer, MD, Roddie, Huw, MD, Rudin, Claudius, MD, Cook, Gordon, MD, Jackson, Graham H, Prof, Child, J Anthony, Prof

“…Summary Background Bisphosphonates reduce the risk of skeletal events in patients with malignant bone disease, and zoledronic acid has shown potential…”
Get full text

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis by Morgan, Gareth J., Gregory, Walter M., Davies, Faith E., Bell, Sue E., Szubert, Alexander J., Brown, Julia M., Coy, Nuria N., Cook, Gordon, Russell, Nigel H., Rudin, Claudius, Roddie, Huw, Drayson, Mark T., Owen, Roger G., Ross, Fiona M., Jackson, Graham H., Child, J. Anthony

“…Thalidomide maintenance has the potential to modulate residual multiple myeloma (MM) after an initial response. This trial compared the effect of thalidomide…”
Get full text

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients by Jones, John R, Weinhold, Niels, Ashby, Cody, Walker, Brian A, Wardell, Chris, Pawlyn, Charlotte, Rasche, Leo, Melchor, Lorenzo, Cairns, David A, Gregory, Walter M, Johnson, David, Begum, Dil B, Ellis, Sidra, Sherborne, Amy L, Cook, Gordon, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Jackson, Graham H, Davies, Faith E, Greaves, Mel, Morgan, Gareth J

“…The emergence of treatment resistant sub-clones is a key feature of relapse in multiple myeloma. Therapeutic attempts to extend remission and prevent relapse…”
Get full text

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer by PLATT, Fiona M, HURST, Carolyn D, TAYLOR, Claire F, GREGORY, Walter M, HARNDEN, Patricia, KNOWLES, Margaret A

“…Purpose: The phosphatidylinositol 3-kinase (PI3K) pathway can be activated by alterations affecting several pathway components. For rational application of…”
Get full text

Genomic evidence for the parallel evolution of coastal forms in the Senecio lautus complex by Roda, Federico, Ambrose, Luke, Walter, Gregory M., Liu, Huanle L., Schaul, Andrea, Lowe, Andrew, Pelser, Pieter B., Prentis, Peter, Rieseberg, Loren H., Ortiz-Barrientos, Daniel

“…Instances of parallel ecotypic divergence where adaptation to similar conditions repeatedly cause similar phenotypic changes in closely related organisms are…”
Get full text

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma by Pawlyn, Charlotte, Kaiser, Martin F, Heuck, Christoph, Melchor, Lorenzo, Wardell, Christopher P, Murison, Alex, Chavan, Shweta S, Johnson, David C, Begum, Dil B, Dahir, Nasrin M, Proszek, Paula Z, Cairns, David A, Boyle, Eileen M, Jones, John R, Cook, Gordon, Drayson, Mark T, Owen, Roger G, Gregory, Walter M, Jackson, Graham H, Barlogie, Bart, Davies, Faith E, Walker, Brian A, Morgan, Gareth J

“…Epigenetic dysregulation is known to be an important contributor to myeloma pathogenesis but, unlike other B-cell malignancies, the full spectrum of somatic…”
Get full text

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial by Jackson, Graham H, Pawlyn, Charlotte, Cairns, David A, de Tute, Ruth M, Hockaday, Anna, Collett, Corinne, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Rocci, Alberto, Snowden, John A, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Drayson, Mark T, Gregory, Walter M, Kaiser, Martin F, Owen, Roger G, Davies, Faith E, Morgan, Gareth J

“…Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral…”
Get full text

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial by Jackson, Graham H, Davies, Faith E, Pawlyn, Charlotte, Cairns, David A, Striha, Alina, Collett, Corinne, Waterhouse, Anna, Jones, John R, Kishore, Bhuvan, Garg, Mamta, Williams, Cathy D, Karunanithi, Kamaraj, Lindsay, Jindriska, Allotey, David, Shafeek, Salim, Jenner, Matthew W, Cook, Gordon, Russell, Nigel H, Kaiser, Martin F, Drayson, Mark T, Owen, Roger G, Gregory, Walter M, Morgan, Gareth J, Clinical Studies Group, Uk Ncri Haematological Oncology

“…The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question…”
Get full text

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial by Morgan, Gareth J, Prof, Child, J Anthony, Prof, Gregory, Walter M, Prof, Szubert, Alex J, MSc, Cocks, Kim, MSc, Bell, Sue E, DPhil, Navarro-Coy, Nuria, MPhil, Drayson, Mark T, MD, Owen, Roger G, MD, Feyler, Sylvia, MD, Ashcroft, A John, MD, Ross, Fiona M, DPhil, Byrne, Jennifer, MD, Roddie, Huw, MD, Rudin, Claudius, MD, Cook, Gordon, MD, Jackson, Graham H, Prof, Wu, Ping, MSc, Davies, Faith E, MD

“…Summary Background Bisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with bone lesions from multiple…”
Get full text

Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests by Heaney, Jennifer L. J., Campbell, John P., Griffin, Anne E., Birtwistle, Jane, Shemar, Meena, Child, J Anthony, Gregory, Walter M., Cairns, David A., Morgan, Gareth, Jackson, Graham, Drayson, Mark T.

“…Summary This study aims to guide the integration of serum free light chain (sFLC) tests into clinical practice, including a new rapid test (Seralite®). Blood…”
Get full text

A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia by Howard, Dena R, Hockaday, Anna, Brown, Julia M, Gregory, Walter M, Todd, Susan, Munir, Tahla, Oughton, Jamie B, Dimbleby, Claire, Hillmen, Peter

“…The FLAIR trial in chronic lymphocytic leukaemia has a randomised, controlled, open-label, confirmatory, platform design. FLAIR was successfully amended to…”
Get full text

Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome by DICKENS, Nicholas J, WALKER, Brian A, ROSS, Fiona M, DAVIES, Faith E, MORGAN, Gareth J, LEONE, Paola E, JOHNSON, David C, BRITO, José L, ZEISIG, Athanasia, JENNER, Matthew W, BOYD, Kevin D, GONZALEZ, David, GREGORY, Walter M

“…Myeloma is a clonal malignancy of plasma cells. Poor-prognosis risk is currently identified by clinical and cytogenetic features. However, these indicators do…”
Get full text

CONVERGENCE AND DIVERGENCE DURING THE ADAPTATION TO SIMILAR ENVIRONMENTS BY AN AUSTRALIAN GROUNDSEL by Roda, Federico, Liu, Huanle, Wilkinson, Melanie J., Walter, Gregory M., James, Maddie E., Bernal, Diana M., Melo, Maria C., Lowe, Andrew, Rieseberg, Loren H., Prentis, Peter, Ortiz-Barrientos, Daniel

“…Adaptation to replicate environments is often achieved through similar phenotypic solutions. Whether selection also produces convergent genomic changes in…”
Get full text

Improved risk stratification in myeloma using a microRNA‐based classifier by Wu, Ping, Agnelli, Luca, Walker, Brian A., Todoerti, Katia, Lionetti, Marta, Johnson, David C., Kaiser, Martin, Mirabella, Fabio, Wardell, Christopher, Gregory, Walter M., Davies, Faith E., Brewer, Daniel, Neri, Antonino, Morgan, Gareth J.

“…Summary Multiple myeloma (MM) is a heterogeneous disease. International Staging System/fluorescence hybridization (ISS/FISH)‐based model and gene expression…”
Get full text

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen by de Tute, Ruth M, Rawstron, Andy C, Gregory, Walter M, Child, J Anthony, Davies, Faith E, Bell, Sue E, Cook, Gordon, Szubert, Alexander J, Drayson, Mark T, Jackson, Graham H, Morgan, Gareth J, Owen, Roger G

Get full text

Genetic Factors Underlying the Risk of Thalidomide-Related Neuropathy in Patients With Multiple Myeloma by JOHNSON, David C, CORTHALS, Sophie L, VAN NESS, Brian, CHILD, J. Anthony, SONNEVELD, Pieter, MORGAN, Gareth J, WALKER, Brian A, ROSS, Fiona M, GREGORY, Walter M, DICKENS, Nicholas J, LOKHORST, Henk M, GOLDSCHMIDT, Hartmut, DAVIES, Faith E, DURIE, Brian G. M

“…To indentify genetic variation that can modulate and predict the risk of developing thalidomide-related peripheral neuropathy (TrPN). We analyzed DNA from…”
Get full text

Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial by Howard, Dena R, Munir, Talha, McParland, Lucy, Rawstron, Andy C, Chalmers, Anna, Gregory, Walter M, O'Dwyer, John L, Smith, Alison, Longo, Roberta, Varghese, Abraham, Smith, Alexandra, Hillmen, Peter

“…The conventional frontline therapy for fit patients with chronic lymphocytic leukaemia (CLL) is fludarabine, cyclophosphamide and rituximab (FCR). Rituximab…”
Get full text